Resistance to TSH (RTSH) is a recently described syndrome of reduced sensitivity to TSH that manifests as euthyroid hyperthyrotropinemia. It is usually identified at birth during routine neonatal screening for congenital hypothyroidism. In less than 2 yr, 13 subjects with RTSH belonging to 8 families have been reported, and all were shown to harbor mutations in the TSH receptor (TSHR) gene. We now report the occurrence of RTSH in 3 unrelated families. Contrary to previous reports, the inheritance of RTSH in 2 of the families was dominant rather than recessive and was not associated with abnormalities in the TSHR gene. Abnormalities in the TSHR gene were excluded by sequencing all coding sequences, exon/intron junctions, and the promoter region of the gene. Furthermore, the involvement of the TSHR in the manifestation of the RTSH phenotype was excluded in 2 families by linkage analysis using intragenic polymorphic markers. We excluded defects in the TSH ␤-subunit by sequencing its gene and by showing that the circulating TSH in affected subjects from all families had normal bioactivity. Also, no abnormalities were found in the G s ␣ gene of one family analyzed by GC-clamped denaturing gradient gel electrophoresis. This study shows that RTSH may be a manifestation of several different genetic defects that requires the exploration of other candidate genes involved in the TSH-TSHR-G s ␣ cascade and genes participating in its regulation. (J Clin Endocrinol Metab 82: [3933][3934][3935][3936][3937][3938][3939][3940] 1997) T SH IS THE principal hormone that controls thyroid gland growth, metabolism, and function, ultimately resulting in thyroid hormone synthesis and secretion (1). These effects are mediated through binding to the extracellular domain of the TSH receptor (TSHR) located on the plasma membrane of thyroid follicular cells. The TSHR belongs to a superfamily of guanine nucleotide-binding (G) protein-coupled receptors that have a common structure, consisting of seven transmembrane segments, three extracellular and three intracellular loops, an extracellular aminoterminus, and an intracytoplasmic carboxyl-terminus (2). Members of the subfamily that includes the TSH, LH/CG, and FSH receptors have long amino-terminal domains that are responsible for the specificity of hormone recognition and binding (3) (4) (5) .
T SH IS THE principal hormone that controls thyroid gland growth, metabolism, and function, ultimately resulting in thyroid hormone synthesis and secretion (1) . These effects are mediated through binding to the extracellular domain of the TSH receptor (TSHR) located on the plasma membrane of thyroid follicular cells. The TSHR belongs to a superfamily of guanine nucleotide-binding (G) protein-coupled receptors that have a common structure, consisting of seven transmembrane segments, three extracellular and three intracellular loops, an extracellular aminoterminus, and an intracytoplasmic carboxyl-terminus (2) . Members of the subfamily that includes the TSH, LH/CG, and FSH receptors have long amino-terminal domains that are responsible for the specificity of hormone recognition and binding (3) (4) (5) .
The interaction between glycoprotein hormones and their receptors is believed to cause a structural change in the receptor activating the G proteins. Being preferentially coupled to G s , this results in the stimulation of adenylyl cyclase and the generation of intracellular cAMP. At high concentrations of the hormones, the receptors also couple to G q , stimulating the production of inositol phosphate through the phospholipase C-dependent regulatory cascade (6 -8) .
As the TSHR is responsible for mediation of the first step in TSH action, the TSHR gene is a potential candidate for mutations causing thyrocyte dysfunction. Defects at the gene level could, theoretically, affect transcription, translation, or protein structure, resulting in failure of synthesis, membrane localization, binding, or response to the ligand (9) . The isolation and sequencing of the human TSHR (10, 11) have provided the opportunity to evaluate TSHR gene abnormalities at the molecular level, which was further facilitated by the availability of genomic sequences at the intron/exon junctions (12) .
Somatic and germline mutations causing constitutive activation (gain of function) of the TSHR produce hereditary nonautoimmune hyperthyroidism (13) and toxic thyroid adenomas (14, 15) , respectively. This finding preceded by 2 yr the first description of loss of function mutations in the TSHR, producing resistance to TSH (RTSH) in individuals harboring different mutations in each of the two alleles (compound heterozygotes) (16) . Within 1 yr, seven additional families manifesting RTSH were identified (17) (18) (19) . In these individuals, as in those described earlier, the phenotype of RTSH manifested as elevated serum levels of TSH on repeated determinations in a background of clinical euthyroidism and in association with normal concentrations of free T 4 , because the syndrome was caused by mutant TSHRs with reduced function. Recently, a family has been identified in which particularly severe loss of TSHR function produced congenital hypothyroidism (high TSH and low free T 4 ) in the homozygotes (20) . In all, the inheritance of RTSH was recessive, usually compound heterozygous, except for two families in which it was homozygous (17, 20) .
In the present study, we report three unrelated families in whom affected individuals manifest the phenotype of RTSH. However, in contrast to those reported previously, no mutations were found in TSHR or TSH␤ gene. Furthermore, in two families, linkage of the TSHR gene to the RTSH phenotype was excluded by haplotyping, and in another family, no putative mutation in the G s ␣ gene was found by denaturing gradient gel electrophoresis.
Subjects and Methods Patients
Family 1 (Fig. 1) . The proposita (II-2) was 38 yr old when a TSH level of 7.2 mU/L was found on routine testing. Repeat determination gave a value of 9.8 mU/L. Despite normal free T 4 index (FT 4 I) values of 93 and 129 (normal range for that laboratory, 50 -150), treatment with 0.1 mg l-T 4 daily was begun. On this regimen, TSH declined to 0.6 mU/L, with an increase in the FT 4 I to only 143. However, the treatment was discontinued because of nonspecific malaise.
Blood samples were obtained from the proposita and nine members of her family, including her parents, who had common ancestors four generations earlier. Both parents had elevated serum levels of TSH, as was the case in one sister (II-3) and a brother (II-4). Her other sister (II-1) had an above average level of serum TSH, and two nephews (III-3 and III-4) had serum TSH concentrations in the upper range of normal ( Fig.  1 ). All family members had normal concentration of iodothyronines as well as the FT 4 I. Serum thyroglobulin (TG) and pituitary glycoprotein ␣-subunit (␣SU) concentrations were also within the normal range. TG and thyroid peroxidase antibodies were not detectable.
Family 2 (Fig. 2) . The proposita (III-2) was the product of a normal pregnancy and delivery. Initial neonatal blood screen was reported as elevated TSH. Serum TSH concentrations at 3 and 4 weeks were 40.3 and 34.5 mU/L, with corresponding total T 4 values of 125 and 106 nmol/L and calculated free T 4 within the normal range. Her physical examination was normal, and ultrasound showed a thyroid gland slightly reduced in size. 99m pertechnetate scan showed a gland normal in size, shape, and position. l-T 4 treatment (50 g daily) was initiated at 1 month of age. After 2 weeks, her serum TSH level had declined to 8.3 mU/L. After 6 weeks of this l-T 4 regimen, serum total T 4 was 154 nmol/L, and TSH was 0.55 mU/L. Her growth and development proceeded normally.
The brother of the proposita (III-1) also had an elevated blood TSH at birth that allegedly was not confirmed on repeated assay. His growth and development were normal without l-T 4 treatment. At Fig. 2 . Thyroid peroxidase and TG antibodies were not detected. Serum free T 4 levels, measured by equilibrium dialysis, in subjects I-1 and I-2 were 21 and 15 pmol/L, respectively (normal range, 10 -32).
Family 3 (Fig. 3) . The propositus, a 6-yr-old boy, was born to healthy nonconsanguineous parents. Pregnancy and delivery were unremarkable. Minor congenital malformations suggestive of Townes-Brocks syndrome were present and included a preauricular skin appendage, glandular hypospadias, cutaneous syndactily of the third and fourth toes, and anal atresia with fistula (21) that was repaired surgically. A high blood TSH level of 93 mU/L was detected on neonatal screening, with a total T 4 of 84 nmol/L, which is within the lower limit of normal. Treatment with 37.5 g l-T 4 daily was initiated, resulting in a serum T 4 level of 232 nmol/L and undetectable TSH. At the age of 2 yr, an ultrasound showed a normal thyroid gland, and l-T 4 treatment was discontinued. Two months later, serum T 4 was 121 nmol/L, with a TSH level of 52 mU/L, rising to 117 mU/L 30 min after the iv administration of 70 g TRH. The child continued to develop normally along the 10 -25th percentile for height and weight. Two and a half years after discontinuation of l-T 4 treatment, TSH has risen to 143 mU/L, with a total T 4 of 107 mmol/L, and free T 4 and T 3 were within the normal range. Physical and mental development continued to be normal, although speech therapy was required for progressive sensorineural hearing loss due to the Townes-Brocks syndrome.
A sister (II-2), 3 yr younger, had a normal TSH level at birth, and her thyroid function tests and those of her parents were within the normal range (Fig. 3) .
Tests of thyroid function
Serum total T 4 , T 3 , and rT 3 concentrations were measured by RIAs, and TSH was determined by a third generation chemiluminescence assay (Corning/Nichols Institute, San Juan Capistrano, CA). The serum free T 4 index was calculated as the product of the serum total T 4 and the T 4 resin uptake value (22) . The serum free T 4 concentration was measured by equilibrium dialysis, and the ␣SU was determined by RIA at Nichols Institute (San Juan Capistrano, CA). The RIA for serum TG was an in-house assay, as previously reported (23) . Thyroid peroxidase and TG autoantibodies were measured by agglutination (Fujirebio, Tokyo, Japan).
Measurement of TSH bioactivity
TSH bioactivity in serum was measured in Chinese hamster ovary cells expressing a recombinant human TSHR, as previously described (24) . Two serum pools (A and B) from patients with elevated serum TSH due to mild primary hypothyroidism were processed in the same assay and served as controls.
Sequencing of TSH and TSHR
Venous blood samples were collected in ethylenediamine tetraacetate. Genomic DNA was isolated from leukocytes as previously described (25) . For amplification of the coding sequences of TSH␤, primers were designed to anneal to intronic sequences flanking each exon. Primers used for the amplification of the TSHR were modified from those reported by de Roux et al. (12) , and those selected for the amplification of the TSHR promoter were designed according to the sequence described by Gross et al. (26) . The 5Ј-ends of the primers were degenerated Table  1 ), and 1 min at 72 C, followed by a final extension step of 10 min at 72 C. The primers used are shown in Table 1 , and the precise conditions for amplification by PCR will be provided upon request.
Both manual and automatic sequencing were performed. Automatic sequencing carried out in Chicago used PCR-generated templates from genomic DNA that were purified from low melting agarose gels after electrophoresis. Reactions were run in a Perkin-Elmer 2400 thermal cycler, using FS AmpliTaq DNA polymerase contained in DNA sequencing kits (Perkin-Elmer). After ethanol precipitation, the pellets were dried and dissolved in 1.5 L formamide loading buffer and sequenced in an Applied Biosystems PRISM 377 DNA sequencer (Applied Biosystems, Foster City, CA). In Brussels, direct sequencing was performed on both strands using the Thermosequenase fluorescentlabeled primer cycle sequencing kit (RPN 2436, Amersham, Aylesbury, UK) according to the manufacturer's recommendations. Samples were loaded on an Applied Biosystems 373 stretch sequencing instrument, and mutations were searched for by the Factura and Sequence Navigator Software (Applied Biosystems).
For manual sequencing, the amplified DNA fragments were cloned into the M13 bacteriophage vector and sequenced by the dideoxynucleotide chain termination reaction (28) (Sequenase version 2.0, U.S. Biochemical Corp., Cleveland, OH). Reaction products were analyzed on 6% acrylamide gel containing 7 mol/L urea. All sequencing primers are listed in Table 1 .
Haplotyping
Four intragenic polymorphic markers were used to haplotype the TSHR alleles to determine linkage of the TSHR gene to the RTSH phenotype in families 1 and 2. Polymorphic nucleotide at position 253 (C/A) in exon 1 was determined by endonuclease digestion (Tth111I, New England BioLabs, Beverly, MA) of the PCR product as previously de- scribed (29) . A polymorphic nucleotide at position Ϫ445 (G/T) in the promoter region was determined by sequencing using primers according to the published sequence (26) . Two microsatellite markers (CA and CT repeats) located in intron 7 of the TSHR (12) were also used for haplotyping. Fragments containing the dinucleotide repeats were amplified by PCR using 10 ng genomic DNA and 0.8 pmol [␥-
32 P]dATP end-labeled forward primers. Each reaction contained, in addition to the labeled primer, 0.2 mmol/L each of dATP, dCTP, dGTP, and dTTP; 0.1 U Taq DNA polymerase; 3.2 pmol unlabeled forward primers; and 4 pmol unlabeled reverse primers in a final volume of 10 L. The PCR was performed in a Perkin-Elmer 9600 thermal cycler. After initial denaturation for 3 min at 95 C, 30 cycles were applied (1 min at 95 C, 1 min at 58 C, and 30 s at 72 C) along with a terminal extension of 5 min at 72 C. The PCR product was denatured for 10 min at 95 C, mixed with loading buffer in 98% formamide, and electrophoresed in a 6% denaturing polyacrylamide gel. Gels were subsequently dried and autoradiographed. A sequence was run in parallel to determine fragment size, and allele numbers were assigned as reported by de Roux et al. (12) .
Screening mutations in the G s ␣ gene by denaturing gradient gel electrophoresis (DGGE)
Each of the 12 exons of the G ␣ s gene were amplified using primers that annealed to flanking intronic sequences. Two microliters of the PCR product were reamplified using one original primer and a primer to which a 40-nucleotide GC sequence adapter was added to the 5Ј-end to serve as a GC clamp. The principle of the technique and primers sequences have been previously described (30, 31) .
The DGGE apparatus and method were those we used and described previously (30) . Polyacrylamide gel slabs containing a linear gradient of denaturants (0 -7 mol/L urea and 0 -40% formamide) were prepared in 6.5% acrylamide in 40 mmol/L Tris, 20 mmol/L sodium acetate, and 1 mmol/L ethylenediamine tetraacetate, pH 7.4. Electrophoresis was performed at 150 V for 8 h at 60 C, maintained by a heater, with continuous mixing of the two chamber buffers with a peristaltic pump. Gels were stained with ethidium bromide for approximately 15 min and photographed under UV light.
Results

The RTSH phenotype: thyroid function and other endocrine tests
The results of thyroid function tests for members of the three families are shown in Figs. 1-3 . All had the cardinal features of RTSH, namely an elevated serum TSH concentration with normal thyroid hormone levels, including free T 4 . These findings were confirmed on repeated determinations, and interference in the TSH assay was excluded by recovery of added TSH to the serum samples. Furthermore, as found in other individuals with this syndrome (16 -19, 32) , their thyroid glands were normal in size and location and, when determined, the perchlorate discharge test was normal. The response to TRH in subject II-4 (family 2) was proportional to the basal TSH value. Serum PRL concentrations were normal in all subjects, as were serum calcium and PTH determined in one affected subject from each family (data not shown). Serum LH, FSH, and estrogen values were also normal in subject II-3 (family 1). These data suggest that the abnormality was confined to the thyroid.
The pattern of inheritance, however, was unusual in families 1 and 2. Contrary to all other cases previously reported (16 -19) , the phenotype followed a dominant mode of inheritance, whether subjects with borderline increases in TSH were considered to be affected or not. The slight increase in serum TG concentration in the affected subjects of family 2 is reminiscent of the case of congenital hypothyroidism and homozygous TSHR mutation described recently (20) .
TSH bioactivity and sequence of the TSH␤ gene
Bioactivity was measured by the relative potency of serum TSH to stimulate cAMP accumulation in cells stably expressing the human TSHR. As shown in Table 2 , values were proportional to the immunoreactive TSH in the three affected subjects tested, each a member of one of the three families. These data are in agreement with the normal concentration of ␣SU in the serum of subjects in family 1. It is also supported by our failure to identify sequence differences in the coding exons of TSH␤ and 10 -100 flanking intronic nucleotides. Both sense and antisense strands of TSH␤ were sequenced from DNAs of subjects I-1 and I-2 (family 1) and the propositi (III-2 and II-1) of families 2 and 3, respectively.
Analysis of the TSHR: sequencing and haplotyping of the gene
All coding exons and flanking intron junctions as well as 514 bp (nucleotides Ϫ1 to Ϫ514 from the translation start point) of the promoter region of the TSHR of subject III-2 from family 2 and subject II-1 of family 3 were sequenced directly in both sense and antisense directions. The TSHR gene of subjects III-1 of family 2 and that of subject II-1 from family 3 were also sequenced independently in Brussels. All coding exons flanking intronic sequences of the TSHR of subjects I-1 and II-3 of family 1 were amplified and subcloned into the M13 vector, and at least 10 templates were sequenced in both directions as described in Materials and Methods. The 5Ј-untranslated region of the TSHR of subject II-2 of family 1 was sequenced directly from the PCR product. Although heterozygosity for the polymorphic nucleotides was detected by direct sequencing, as described below, no other differences were found compared to the wild-type sequence.
Linkage analysis
To exclude the possibility that TSHR gene mutations in the noncoding regions that may affect transcription or produce splicing defects escaped detection by sequencing, we used all known intragenic polymorphic markers for haplotyping. Several of these markers were identified after completion of the sequencing. The analysis was particularly useful because the four markers could identify unique haplotypes for each of the four parental alleles. Results are shown in Figs. 1 and 2. In both families the haplotype data exclude linkage of the TSHR gene to the phenotype of RTSH. Linkage is broken by several members of the family 1 regardless of whether TSH values in the upper limit of normal are included or excluded from the RTSH phenotype. In family 2 ( Fig. 2) , linkage of the phenotype to the TSHR gene is definitely excluded, as the two affected children have inherited a different allele from their affected mother and the same allele from their unaffected father.
Analysis of the G s ␣ gene
No putative mutations in the G s ␣ gene were identified by DGGE in the affected members (I-1, I-2, and II-3) of family 1 (data not shown). A positive control, heterozygous for a mutations in the G s ␣ gene was provided by Dr. Kyoko Takeda. It was used in the analyses and gave positive results.
Discussion
The syndrome of RTSH has been reported in 13 subjects belonging to 8 families (Tables 3 and 4 ). In all of these subjects, mutations in the TSHR gene that reduce the function of its product have been detected and are responsible for the clinical manifestations characteristic of the syndrome. With one exception (32) , affected individuals harbor mutations in both alleles and are either compound heterozygotes or homozygous when consanguineous (17) .
It is of interest that of the eight families with RTSH, five share the same TSHR mutation with at least one other family (Tables 3 and 4 ). The transversion of C to G in nucleotide 583 that results in the replacement of the normal proline 162 with an alanine has been found in three unrelated families (16, 17, 32) , suggesting that it may be relatively prevalent in the population. Furthermore, this mutation has produced increases in serum TSH of variable magnitude, and the researchers have postulated the existence of another, as yet unidentified, mutation in the promoter region of the other allele (32) .
Although the majority of individuals with RTSH maintain a euthyroid state through compensatory hyperthyrotropinemia (16 -19) , the phenotype encompasses a broader range of thyroid function, with transient and even permanent congenital hypothyroidism at the extreme (20) . This depends in part on the residual function displayed by the least affected mutant allele. In all cases a eutopic thyroid gland deviates only slightly from the normal size. Absolute hormone values are quite variable. TSH concentrations range from just above the upper limit of normal to 115 mU/L, whereas free T 4 values span the broad range of normal, with the majority of cases in the low normal range (Table 3 ). These differences do not correlate with the degree of functional impairment of the mutant TSHR, with the exception of complete loss of function, resulting in hypothyroidism (20) . Heterozygotes have no distinct phenotype, although borderline increases in serum TSH have been observed (Table 4) . We now report three unrelated families expressing the typical RTSH phenotype, yet it occurs in the absence of a defect in the TSHR. Although failure to identify a mutation by sequencing of genomic DNA does not fully exclude the presence of a mutation that affects expression, the absence of genetic linkage to the phenotype in families 1 and 2 definitely excludes the involvement of TSHR. The normal TSH bioactivity and normal coding sequence of TSH␤ in all three families also exclude involvement of the TSH gene in expression of the phenotype.
Mutations in the signaling pathway, downstream of the TSHR, that produce a partial loss of function could manifest as RTSH, although the defect may not be confined to the thyroid. In fact, germline mutations causing loss of function of the G s ␣ protein have been found to produce RTSH even in the heterozygous individual (33) . Depending on the severity of the defect, the phenotype may be overt hypothyroidism or euthyroidism with elevated serum TSH. However, owing to the ubiquitous expression of G s ␣, the phenotype shows a broader spectrum of disorders involving the parathyroid gland and gonads as well as somatic and skeletal abnormalities, collectively termed Albright's hered- itary osteodystrophy (34) . Although this was not the clinical picture observed in affected members of the three families, we screened for a putative defect in the G s ␣ gene using DGGE in one family and found none. Several other mechanisms may be considered in the manifestation of RTSH. We cannot exclude a reduction in the expression of the TSHR. This could not be due to a defect in the promoter region of the TSHR, as we have sequenced the entire 5Ј-region containing the nucleotide sequences that bind regulatory factors such as insulin growth factor I, thyroid transcription factor-1 (TTF-1), thyroid hormone receptor, and cAMP (5). It is, however, possible for full expression of the TSHR to be prevented by a defect in one of these cofactors. TTF-1 is one such candidate, although it exerts only a modest effect on TSHR gene expression (35, 36) . Considering the more important role of TTF-1 in the regulation of TG and thyroid peroxidase (37) , one would have expected at least an abnormality in the perchlorate discharge test, which was not found in affected subjects from families 1 and 2. A recent search for mutations in the TTF-1 in 76 patients with thyroid dysgenesis yielded negative results (38, 39) . A complete lack of TTF-1, on the other hand, is not compatible with life, because of the role of TTF-1 in the embryogenesis of several vital tissues (40) .
Another possibility is a defect downstream of G s ␣. The human G protein-coupled receptor kinase 5 (GRK5) appears to be the predominant isoform in the thyroid cells (41) . However, the level of its GRK5 messenger ribonucleic acid in the thyroid is not higher than that in other tissues, such as lung, colon, heart, and kidney. Thus, a functional alteration in GRK5 is not expected to produce a phenotype limited to the thyroid. Nevertheless, specific alterations of the molecule could predominantly influence cAMP production in thyroid cells.
In family 2, the modest increase in serum TG may indicate a slight overstimulation of the thyroid gland, which would, in turn, point to the possibility of a minor hormonogenic defect. However, the absence of thyroid hyperplasia is against this view. Of note is the observation of high serum TG levels in two families with TSHR mutations producing a total loss of function and hypothyroidism (20, 42) . Although no definite explanation can be offered, it can be suggested that defective activation of the cAMP regulatory cascade during embryogenesis might lead to a mild disorganization of the follicle structure, resulting in TG leakage.
As is the case with other genetic defects, the same phenotype may be caused not only by defects at different gene levels, but also by the interplay of several genetic and environmental conditions. The syndrome of RTSH does not seem to escape this rule. Abnormal values are in bold. The range of values is given for more than one determination. NG, Not given; NL, normal, value not given.
